Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1

Xin,Zeng-Feng; Shen,Cheng-Chun; Tao,Li-Jiang; Yan,Shi-Gui; Wu,Hao-Bo

doi:10.3892/ijmm.2012.1192

Gambogic acid inhibits invasion of osteosarcoma via upregulation of TIMP-1

Authors:
- Zeng-Feng Xin
- Cheng-Chun Shen
- Li-Jiang Tao
- Shi-Gui Yan
- Hao-Bo Wu
View Affiliations

Affiliations: Department of Orthopedic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China
Published online on: November 21, 2012 https://doi.org/10.3892/ijmm.2012.1192
Pages: 105-112

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gambogic acid (GA), the natural product, has been demonstrated to be a promising chemotherapeutic drug for osteosarcoma (OS) due to its ability to induce apoptosis and cell cycle arrest. To date, no studies have examined the role of GA in metastatic bone disease. Matrix metalloproteinases (MMPs) play critical roles in invasion and metastasis, and the tissue inhibitors of metalloproteinase (TIMP) family regulates the activity of multifunctional metalloproteinases. In this study, we investigated the gene expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in OS cell lines treated by the GA. The expression of MMP-9 and TIMP-1 were studied by reverse transcription-polymerase chain reaction (RT-PCR) and western blotting. In vitro invasion of OS cell lines (Saos-2, MG-63) were investigated by the Matrigel invasion assay. Mean MMP-9 protein and mRNA expression was significantly suppressed; in addition, mean TIMP-1 protein mRNA expression were upregulated by increasing GA concentrations. GA reduced the invasiveness of OS cell lines dose-dependently. Furthermore, specific inhibition of TIMP-1 secretion with siRNA against TIMP-1 significantly reduced the effect of GA on OS cell lines. Overall, our findings suggest that GA reduces the invasive potential of OS cells via attenuation of MMP-9 and upregulation of TIMP-1. Moreover, TIMP-1 played an important role in the reduction of invasive potential of the OS cells which were treated by GA.

View Figures

View References

1	Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 41:2836–2845. 2005.PubMed/NCBI
2	Bielack SS, Kempf-Bielack B, Delling G, Exner GU and Flege S: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar
3	Ferrari S, Briccoli A, Mercuri M, Bertoni F and Picci P: Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol. 21:710–715. 2003. View Article : Google Scholar : PubMed/NCBI
4	Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, van Marck E and Hogendoorn PC: Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Human Genetics. 11:611–618. 2003. View Article : Google Scholar : PubMed/NCBI
5	Link MP: Preoperative and adjuvant chemotherapy in osteosarcoma. Frontiers of Osteosarcoma Research: Interdisciplinary Survey of Clinical and Research Advances. Novak JF and Mcmaster JH: Hogrefe and Huber; Seattle: pp. 41–49. 1993
6	Wolf K and Friedl P: Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis. 26:289–298. 2009. View Article : Google Scholar : PubMed/NCBI
7	Clark IM, Swingler TE, Sampieri CL and Edwards DR: The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 40:1362–1378. 2008. View Article : Google Scholar : PubMed/NCBI
8	Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 92:827–839. 2003. View Article : Google Scholar : PubMed/NCBI
9	Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 3:207–214. 2002. View Article : Google Scholar : PubMed/NCBI
10	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
11	Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
12	Hidalgo M and Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93:178–193. 2001. View Article : Google Scholar : PubMed/NCBI
13	Denhardt DT, Feng B, Edwards DR, Cocuzzi ET and Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 59:329–341. 1993. View Article : Google Scholar : PubMed/NCBI
14	Phillips BW, Sharma R, Leco PA and Edwards DR: A sequence-selective single-strand DNA-binding protein regulates basal transcription of the murine tissue inhibitor of metalloproteinases-1 (Timp-1) gene. J Biol Chem. 274:22197–22207. 1999. View Article : Google Scholar
15	Kossakowska AE, Urbanski SJ and Edwards DR: Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin’s lymphomas. Blood. 77:2475–2481. 1991.
16	Yoshiji H, Gomez DE and Thorgeirsson UP: Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int J Cancer. 69:131–134. 1996. View Article : Google Scholar : PubMed/NCBI
17	Fong KM, Kida Y, Zimmerman PV and Smith PJ: TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res. 2:1369–1372. 1996.PubMed/NCBI
18	Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 127:151–156. 2005.PubMed/NCBI
19	Korpi JT, Hagström J, Lehtonen N, et al: Expression of matrix metalloproteinases-2, -8, -13, -26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol. 20:e18–e22. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhao W, Zhou SF, Zhang ZP, Xu GP, Li XB and Yan JL: Gambogic acid inhibits the growth of osteosarcoma cells in vitro by inducing apoptosis and cell cycle arrest. Oncol Rep. 25:1289–1295. 2011.
21	Guo QL, You QD, Wu ZQ, Yuan ST and Zhao L: General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacol Sin. 25:769–774. 2004.PubMed/NCBI
22	Yu J, Guo QL, You QD, et al: Gambogic acid-induced G(2)/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis. 28:632–638. 2007. View Article : Google Scholar : PubMed/NCBI
23	Kasibhatla S, Jessen KA, Maliartchouk S, et al: A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA. 102:12095–12100. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chen J, Gu HY, Lu N, et al: Microtubule depolymerization and phosphorylation of c-Jun n-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma McF-7 cells. Life Sci. 83:103–109. 2008. View Article : Google Scholar : PubMed/NCBI
25	Wu ZQ, Guo QL, You QD, Zhao L and Gu HY: Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull. 27:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
26	Guo Q, Qi Q, You Q, Gu H, Zhao L and Wu Z: Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol. 99:178–184. 2006. View Article : Google Scholar : PubMed/NCBI
27	Qi Q, You Q, Gu H, et al: Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol. 117:433–438. 2008. View Article : Google Scholar : PubMed/NCBI
28	Qi Q, Lu N, Wang XT, et al: Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol. 86:386–395. 2008. View Article : Google Scholar : PubMed/NCBI
29	Zhang S, Li L, Lin JY and Lin H: Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 9:899–904. 2003.PubMed/NCBI
30	Seo YS, Park JJ, Kim JH, et al: Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci. 52:753–759. 2007. View Article : Google Scholar : PubMed/NCBI
31	Guruvayoorappan C and Kuttan G: Amentoflavone inhibits experimental tumor metastasis through a regulatory mechanism involving MMP-2, MMP-9, prolyl hydroxylase, lysyl oxidase, VEGF, ERK-1, ERK-2, STAT-1, NM23 and cytokines in lung tissues of C57BL/6 mice. Immunopharmacol Immunotoxicol. 30:711–727. 2008. View Article : Google Scholar
32	Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T and Hendriks T: Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg. 90:1556–1564. 2003. View Article : Google Scholar : PubMed/NCBI